MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select…
MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year…
The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic models MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of the…
Trios from 200 families who have lost a child to SUDC to be sequenced on PacBio’s Revio system with SPRQ-Nx chemistry, enabling increased diagnostic yield for grieving families MENLO PARK,…
Q4 2025 revenue growth of 14% year-over-year, driven by strong Revio and Vega shipments and record consumables revenue MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB),…
Community-developed approach combines multi-contact 3C with HiFi sequencing to deliver haplotype-resolved assemblies from minimal input material MENLO PARK, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of…
MENLO PARK, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the…
MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside…
MENLO PARK, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the…
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025 Q3…
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025 Q3…
New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics…
NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia MENLO PARK, Calif., Nov. 04,…
MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results…
New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ:…
If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.